Keyphrases
Additional Resources
50%
Age-related Macular Degeneration
100%
Best-corrected Visual Acuity
100%
Decision Maker
50%
Initial Treatment
100%
Intravitreal Bevacizumab
100%
Intravitreal Injection
100%
Intravitreal Ranibizumab
50%
Largest Mean
50%
Long Interval
50%
Macular Volume
100%
Myopic Choroidal Neovascularization (mCNV)
100%
Naïve Eyes
50%
Optical Coherence Tomography
50%
Outcome Costs
50%
Patients Included
50%
Realistic Scenario
50%
Retinal Volume
50%
Short Intervals
100%
Visual Acuity
100%
Visual Outcome
50%
Nursing and Health Professions
Age Related Macular Degeneration
66%
Best Corrected Visual Acuity
66%
Bevacizumab
100%
Cohort Analysis
33%
Hospital
33%
Intravitreal Drug Administration
66%
Optical Coherence Tomography
33%
Physician
33%
Subretinal Neovascularization
66%
Visual Acuity
100%
Medicine and Dentistry
Age Related Macular Degeneration
66%
Best Corrected Visual Acuity
66%
Bevacizumab
100%
Choroidal Neovascularization
66%
Cohort Analysis
33%
Health Care Cost
33%
Intravitreal Administration
66%
Optical Coherence Tomography
33%
Visual Acuity
100%
Neuroscience
Age-Related Macular Degeneration
66%
Bevacizumab
100%
Choroidal Neovascularization
66%